Angela Garding
University of Ulm
18 Papers
91 Citations
Angela Garding is an academic researcher from University of Ulm. The author has contributed to research in topics: Regulation of gene expression & Biology. The author has an hindex of 14, co-authored 16 publications. Previous affiliations of Angela Garding include German Cancer Research Center.
Chat about Author
Papers
Mapping gene regulatory circuitry of Pax6 during neurogenesis
Sudhir Thakurela,Neha Tiwari,Sandra Schick,Angela Garding,Robert Ivanek,Benedikt Berninger,Vijay K. Tiwari +6 more
TL;DR: New aspects of the gene regulatory circuitry of Pax6 are demonstrated, revealing how it functions to control neuronal development at multiple levels to ensure unidirectionality and proper execution of the neurogenic program.
Direct pericyte-to-neuron reprogramming via unfolding of a neural stem cell-like program
Marisa Karow,Marisa Karow,J. Gray Camp,Sven Falk,Tobias Gerber,Abhijeet Pataskar,Malgorzata Gac-Santel,Jorge Kageyama,Agnieska Brazovskaja,Angela Garding,Wenqiang Fan,Therese Riedemann,Antonella Casamassa,Antonella Casamassa,Andrej Smiyakin,Christian Schichor,Magdalena Götz,Vijay K. Tiwari,Barbara Treutlein,Barbara Treutlein,Benedikt Berninger +20 more
TL;DR: It is shown that successful direct reprogramming of adult human brain pericytes into functional iNs by Ascl1 and Sox2 encompasses transient activation of a neural stem cell-like gene expression program that precedes bifurcation into distinct neuronal lineages.
Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia
Danilo Allegra,Danilo Allegra,V. Bilan,Angela Garding,Hartmut Döhner,S. Stilgenbauer,Florian Kuchenbauer,Daniel Mertens,Daniel Mertens +8 more
TL;DR: It is shown that, apart from genomic deletion or transcriptional downregulation, aberrant processing of miRNA leads to specific reduction of miRNAs in leukemic cells, representing a novel oncogenic mechanism in the pathogenesis of CLL.
71
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
Christine Wolf,Angela Garding,Katharina Filarsky,Jasmin Bahlo,Sandra Robrecht,Natalia Becker,Manuela Zucknick,Arefeh Rouhi,Anja Weigel,Rainer Claus,Dieter Weichenhan,Barbara Eichhorst,Kirsten Fischer,Michael Hallek,Florian Kuchenbauer,Christoph Plass,Hartmut Döhner,Stephan Stilgenbauer,Peter Lichter,Daniel Mertens,Daniel Mertens +20 more
TL;DR: The results indicate that the aberrant activation of NFATC1 by DNA hypomethylation and BCR signaling plays a major role in the pathomechanism of CLL.
38
JNK-dependent gene regulatory circuitry governs mesenchymal fate.
Sanjeeb Kumar Sahu,Angela Garding,Neha Tiwari,Sudhir Thakurela,Joern Toedling,Susanne Gebhard,Felipe Ortega,Nikolai Schmarowski,Benedikt Berninger,Robert Nitsch,Marcus Schmidt,Vijay K. Tiwari +11 more
TL;DR: A kinetically distinct role for the JNK pathway is uncovered in defining the transcriptome that underlies mesenchymal identity and novel transcription factors that mediate these responses during development and disease are revealed.
35